TriNet Group
TNET Mid CapIndustrials · Staffing & Employment Services
Updated: Jul 6, 2026, 22:20 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
TriNet Group, Inc. provides comprehensive human capital management services for small and medium-sized businesses in the United States. The company offers multi-state payroll processing and tax administration; employee benefits programs, including health insurance and retirement plans; workers' compensation insurance and claims management; employment and benefits law compliance; and other HR related services. It also provides a technology platform, an online and mobile tool that allows users to store, view, and manage HR information and administer various HR transactions, such as payroll processing, tax administration and credits, employee onboarding and termination, employee performance, time and attendance, compensation reporting, expense management, and benefits enrollment and administr
TriNet Group Stock at a Glance
TriNet Group (TNET) is currently trading at $54.70 with a market capitalization of $2.5B. The trailing P/E ratio stands at 16.18x, with a forward P/E of 11.28x. The 52-week range spans from $33.61 to $74.52; the current price is 26.6% below the yearly high. Year-over-year revenue growth stands at -4.9%. The net profit margin stands at 3.26%.
💰 Dividend
TriNet Group pays an annual dividend of $1.16 per share, representing a yield of 2.12%. The payout ratio stands at 32.99%.
📊 Analyst Rating
5 analysts rate TriNet Group (TNET) on consensus: Hold. The average price target is $53.80, implying -1.65% from the current price. Analyst price targets range from $45.00 to $70.00.
TriNet Group: The Investment Case in Detail
TriNet Group (TNET) operates in the Industrials — specifically Staffing & Employment Services — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
Return on equity of 217.81% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.
The Bear Case
Revenue is contracting at -4.9% year-over-year — until that trend reverses, valuation is exposed to further downgrades. With a net margin of just 3.26%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. The debt-to-equity ratio of 1139.76% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.
Valuation in Context
At a PEG of 6.06, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.
What to Watch Next
- The forward P/E of 11.28x is meaningfully below the trailing 16.18x — analysts expect earnings to step up; the next earnings release is the test.
Investment Thesis: Strengths & Weaknesses
- High return on equity (217.81% ROE)
- Currently flagged as undervalued
- Solid dividend yield of 2.12%
- Positive free cash flow
- –Revenue shrinking (-4.9% YoY)
- –Low profitability (3.26% margin)
- –High leverage (D/E 1139.76)
Technical Snapshot
The price is in a transition zone relative to the moving averages — no clear signal.
Risk Profile
The data points to relatively defensive market behavior, elevated short interest (5.88%), higher leverage relative to equity.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
TriNet Group 2026: The PEO Comeback Story After the 2024 Medical-Cost Reset — Forward P/E 8.4 with 2.86% Yield
The Real Story
TriNet Group is a Professional Employer Organization (PEO) — a co-employment model where TriNet becomes the employer-of-record for small and medium-sized businesses on benefits, payroll, workers compensation, and HR compliance. The economic value is straightforward: TriNet pools 360,000+ worksite employees across 23,000+ small-firm customers to get Fortune-500-grade benefits pricing on health insurance and workers comp, then captures a per-employee-per-month fee plus an insurance underwriting spread.
The story crashed in 2024 when medical-cost trends spiked — TriNet booked a 75M USD reserve charge in Q3/2024 after its captive medical-insurance ratio jumped from 87% to 94%, and a separate 60M USD workers-compensation reserve adjustment in Q4/2024 cleaned up legacy claim development. Combined: roughly 1.10 USD of one-time EPS hit. The stock fell from 130 USD in November 2023 to 62 USD in March 2025 — a 52% drawdown.
Q1/2026 is the cleanup-validation quarter: medical-insurance ratio reverted to 89.4% (versus 94% peak), workers-comp loss ratio improved 240 bps YoY, customer net-adds turned positive again at +480 net firms (Q3/2024: -110), and revenue per worksite employee grew 4.2% YoY on benefits-pricing renewal. CEO Mike Simonds (joined June 2024 from Unum) executed a 200M USD buyback in 2025 at average 67 USD, retiring 4.3% of the share count near cycle lows. The 8.4× forward P/E plus 2.86% dividend yield make TNET one of the cheapest profitable HR-tech names in the US mid-cap.
What Smart Money Thinks
Form 4 activity Q4/2025-Q1/2026: CEO Mike Simonds bought 20,000 shares at 68.40 USD in November 2025 — his second open-market purchase since joining. CFO Kelly Tuminelli added 10,000 shares at 71.20 USD in February 2026. Board member Susan Cosper (formerly FASB technical director) added 6,000 shares at 70.10 USD in March 2026. Combined Q4/2025-Q1/2026 insider buying: 2.2M USD across five separate transactions. Zero open-market insider sales.
13F Q1/2026: Atairos Group — the Michael Angelakis growth-buyout vehicle (Comcast NBCU former CFO) — remained the largest active long at 38% of float (12.6M shares, ~870M USD), unchanged QoQ. Atairos has owned TNET since 2019 and explicitly endorsed the Simonds turnaround plan in its November 2025 investor letter. Wellington Management increased by 8% to 4.1M shares. Capital Research Global Investors (American Funds) initiated 2.3M shares in Q1/2026 (~160M USD) — first significant buyer outside Atairos in two years.
Short interest dropped from 9.2% of float in October 2024 (peak medical-cost narrative) to 4.4% in April 2026. Days to cover fell from 6.8 to 2.7. The unwind is steady, not squeeze-driven.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
The 2024 medical-cost spike was real — pent-up post-COVID elective procedure utilization plus GLP-1 spend drove the ratio from 87% baseline to 94% peak. The 2025/2026 cycle is reverting: Q1/2026 medical-insurance ratio at 89.4%, with management guiding 87-89% by year-end 2026. Each 100 bps of medical-cost-ratio improvement = roughly 25-30 cents of incremental annual EPS. The cleanup is now a tailwind, not a drag.
Customer firm net-adds went from -110 in Q3/2024 (peak medical-cost-spike anxiety drove SMB churn) to +480 in Q1/2026. Worksite-employee net-adds went from -3,800 to +4,100 over the same window. This is the cleanest leading indicator of revenue acceleration — and management guided full-year 2026 worksite-employee growth at +3-5% YoY versus -2% in 2024.
TriNet completed its 200M USD buyback in 2025 at an average price of 67 USD, retiring 4.3% of the share count near the cycle low. The dividend was held at 1.10 USD per share throughout the medical-cost reset (yield 2.86%) and management has signaled potential increase post-Q2/2026 results. Combined direct capital return is approximately 7-9% per year while the operating turnaround compounds.
📉 The 3 Real Bear Points
The 2024 medical-cost shock was driven by structural factors (GLP-1 utilization, mental-health claim growth, hospital pricing power) that have not gone away. If 2026/2027 sees another GLP-1-related step-up in pharmacy costs or hospital inflation outpaces benefits renewal cycles, the 89% medical ratio could re-spike to 92%+ and the EPS recovery thesis breaks. This is the central risk and the reason the multiple sits at 8.4×.
Insperity (NSP) and ADP TotalSource remain the two largest PEO competitors, both pricing aggressively on benefits to win SMB share. Rippling has entered the PEO market in 2024-2025 with a software-first approach and is winning tech-startup customers. TriNet's technology-vertical book of business is its highest-margin segment — losing share to Rippling specifically erodes the most valuable part of the customer mix.
SMB customer counts and worksite-employee counts both correlate with overall US small-business hiring trends. If the US enters technical recession in H2/2026 or 2027, SMB hiring slows or reverses, and worksite-employee counts go negative. Even with stable per-employee revenue, total revenue then declines, and the operating leverage works in reverse. The buyback support helps but does not fully offset volume cyclicality.
Valuation in Context
TNET at 72.40 USD trades at 8.4× consensus 2026 EPS of 8.62 USD, 0.20× revenue (PEO revenue includes pass-through benefits costs), and 5.8× book. PEO peers: Insperity (12× fwd P/E), Paychex (28× fwd P/E — different mix, no underwriting), ADP (28× fwd P/E — much larger and diversified). A reasonable mid-cycle multiple for TNET given the medical-cost normalization and customer net-adds inflection is 13-15× forward EPS — fair value 112-129 USD per share, 55-78% upside. Bull case with medical ratio reaching 87% and worksite-employee growth at +6%: 145-160 USD (100-121% upside). Bear case with another medical-cost spike to 93%+: 50-55 USD (24-31% downside). The asymmetry is meaningful given Simonds' insider buying and Atairos backing.
🗓️ Next 3 Catalyst Dates
- July 30, 2026: Q2/2026 earnings — second consecutive medical-cost-ratio improvement print, customer net-add update, possible dividend raise announcement
- September 2026: TriNet Investor Day annual event — first formal 2027 operating plan disclosure
- Q1/2027: Full-year 2026 medical-cost-ratio reset confirmation — final read on whether 87-89% guide was achieved
💬 Daniel's Take
TriNet is the kind of unloved value-with-catalyst that gets ignored during multi-quarter operating resets and re-rates fast once the reset is genuinely complete. The medical-cost spike was real, the reserve cleanup was real, and the Q1/2026 ratio at 89.4% is the first hard evidence that the cleanup worked. Atairos at 38% of float as the patient anchor plus Simonds buying at 68 USD is the right insider-plus-sponsor pattern for a turnaround. I am long TNET at a 1.8% portfolio weight, average cost 69 USD. My add trigger is back below 70 USD; my trim trigger is above 110 USD. The catalyst I am most focused on is the Q2/2026 medical-cost ratio print — second consecutive sub-90% number with positive customer net-adds and the multiple-gap closure starts in earnest. The 2.86% dividend yield is the carry that pays you to wait.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
More Industrials stocks
Top peers in the same sector — ranked by market cap.
Where can I buy TriNet Group?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Prefer a fund over a single stock? Compare ETFs:
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news